Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance

  • Vives Armengol, Joaquim
  • Hernandez, Joaquim
  • Clementine, Mirabel
  • Puigdomenech-Poch, Maria
  • Romeo-Guitart, David
  • Marmolejo Martínez-Artesero, Sara
  • Cabrera Perez, Raquel
Animal model; Cell therapy; Mesenchymal stromal cells, Modelo animal; Terapia celular; Células estromales mesenquimales, Model animal; Teràpia cel·lular; Cèl·lules estromals mesenquimàtiques, Background: the use of Mesenchymal Stromal Cells (MSC) in emerging therapies for spinal cord injury (SCI) hold the potential to improve functional recovery. However, the development of cell-based medicines is challenging and preclinical studies addressing quality, safety and efficacy must be conducted prior to clinical testing; (2) Methods: herein we present (i) the characterization of the quality attributes of MSC from the Wharton’s jelly (WJ) of the umbilical cord, (ii) safety of intrathecal infusion in a 3-month subchronic toxicity assessment study, and (iii) efficacy in a rat SCI model by controlled impaction (100 kdynes) after single (day 7 post-injury) and repeated dose of 1 × 106 MSC,WJ (days 7 and 14 post-injury) with 70-day monitoring by electrophysiological testing, motor function assessment and histology evaluation; (3) Results: no toxicity associated to MSC,WJ infusion was observed. Regarding efficacy, recovery of locomotion was promoted at early time points. Persistence of MSC,WJ was detected early after administration (day 2 post-injection) but not at days 14 and 63 post-injection. (4) Conclusions: the safety profile and signs of efficacy substantiate the suitability of the presented data for inclusion in the Investigational Medicinal Product Dossier for further consideration by the competent Regulatory Authority to proceed with clinical trials., This work has been developed in the context of the Spanish Cell Therapy Network (TerCel, expedient No.’s RD16/0011/0014, RD16/0011/0028 and RD16/00111/0036) and supported by Fundació La Marató de TV3 (grant No. 616/2012) and BST internal funding. Work in J.G.-L.’s laboratory is supported by the Spanish Advanced Therapy Network funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III (TERAV, expedient No.’s RD21/0017/0008 and RD21/0017/0022), CIBERNED (CB06/05/1105), and J.V.’s laboratory is a Consolidated Research Group (ref. 2017SGR719) by the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use

  • Torrents, Sílvia
  • Escudero del Moral, Andrés
  • Codinach, Margarita
  • Rodríguez Gómez, Luciano
  • Querol, Sergio
  • Vives, Joaquim
Immunomodulation; Mesenchymal stromal cells; Quality & regulatory compliance, Immunomodulació; Cèl·lules estromals mesenquimàtiques; Qualitat i compliment normatiu, Inmunomodulación; Células estromales mesenquimales; Calidad y cumplimiento normativo, Multipotent mesenchymal stromal cells (MSC) offer new therapeutic opportunities based on their ability to modulate an imbalanced immune system. Immunomodulatory potency is typically demonstrated in vitro by measuring the presence of surrogate markers (i.e., indoleamine-2,3-dioxygenase, IDO; tumor necrosis factor receptor type 1, TNFR1) and/or functional assays in co-cultures (i.e., inhibition of lymphoproliferation, polarization of macrophages). However, the biological variability of reagents used in the latter type of assays leads to unreliable and difficult to reproduce data therefore making cross-comparison between batches difficult, both at the intra- and inter-laboratory levels. Herein, we describe a set of experiments aiming at the definition and validation of reliable biological reagents as a first step towards standardization of a potency assay. This approach is based on the co-culture of Wharton’s jelly (WJ)-derived MSC and cryopreserved pooled peripheral blood mononuclear cells. Altogether, we successfully defined a robust and reproducible immunopotency assay based on previously described methods incorporating substantial improvements such as cryopreservation of multiple vials of pooled peripheral blood mononuclear cells (PBMC) from 5 individual donors that enable a number of tests with same reagents, also reducing waste of PBMC from individual donors and therefore contributing to a more efficient and ethical method to use substances of human origin (SoHO). The new methodology was successfully validated using 11 batches of clinical grade MSC,WJ. Methods described here contribute to minimize PBMC donor variability while reducing costs, streamlining assay setup and convenience and laying the foundations for harmonization of biological reagents usage in standardized immunopotency assays for MSC., Open Access Funding provided by Universitat Autonoma de Barcelona. This work has been developed in the context of Red Española de Terapias Avanzadas (TERAV, expedient no. RD21/0017/0022) funded by Instituto de Salud Carlos III (ISCIII) in the context of NextGenerationEU’s Recovery, Transformation and Resilience Plan and by the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (2017 SGR 719).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance

  • Vives Armengol, Joaquim
  • Sòria, Maria Glòria
  • McGrath, Eoin
  • Magri, Mara
Integrated management system; Quality compliance; Quality standards, Sistema de gestión integrado; Cumplimiento de la calidad; Estándares de calidad, Sistema de gestió integrat; Compliment de la qualitat; Estàndards de qualitat, Cell therapies are required to meet with compulsory regulations that co-exist with other optional standards and guidelines that together compose a complex quality management system. Indeed, reliable insights on the mechanisms of action and safety of novel cell-based therapies require adherence to solid quality management structures in all steps of the value chain, from early research and tissue procurement to clinical trials and biovigilance, thus guaranteeing reproducibility and solid foundations for better science and improved clinical practice. Herein we present the concept of the quality ecosystem as a tool to understand and assist all stakeholders involved in developing and structuring the integration of standards as novel developments are taking place. We conclude that the various quality management initiatives can all be thought about under the umbrella of an ecosystem., Work in JV’s laboratory is supported by the Spanish Advanced Therapy Network (TERAV, expedient No. RD21/0017/0022), awarded by the Generalitat de Catalunya as Consolidated Research Group (ref. 2017SGR719) and funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies

  • López Navas, Luis
  • Sílvia Torrents
  • Sanchez-Pernaute, Rosario
  • Vives Armengol, Joaquim
Non-clinical safety; Product development; Quality compliance, Seguridad no clínica; Desarrollo de productos; Cumplimiento de calidad, Seguretat no clínica; Desenvolupament de productes; Compliment de la qualitat, The development of cell-, gene- and tissue engineering (CGT)-based therapies must adhere to strict pharmaceutical quality management standards, as for any other biological or small-molecule drug. However, early developments often failed to fully comply with good laboratory practices (GLP) in non-clinical safety studies. Despite an upward trend of positive opinions in marketing authorization applications, evidence of adherence to the principles of GLP is not openly reported; therefore, their relative impact on the overall quality of the product development program is unknown. Herein we investigated the actual degree of GLP implementation and the underlying factors impeding full compliance in non-clinical developments of CGT-based marketed medicines in the EU and USA, including (i) the co-existence of diverse quality management systems of more strategic value for small organizations, particularly current Good Manufacturing Practices n(GMP); (ii) lack of regulatory pressure to pursue GLP certification; and (iii) the involvement of public institutions lacking a pharmaceutical mindset and resources. As a final reflection, we propose conformity to good research practice criteria not as a doctrinaire impediment to scientific work, but as a facilitator of efficient clinical translation of more effective and safer innovative therapies., The authors received no specific funding for this work, which has been developed in the context of Red Española de Terapias Avanzadas (TERAV, expedient no.’s RD21/0017/0015 and RD21/0017/0022) funded by Instituto de Salud Carlos III (ISCIII) in the context of NextGenerationEU’s Recovery, Transformation and Resilience Plan.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immunocompatibility in transplantation: adapting to a changing therapeutic landscape

  • Güell-Alonso, Raquel
  • Cabrera Pérez, Raquel
  • Vives, Joaquim
Compatibilitat HLA; Teràpies emergents; Immunosupressió, HLA match; Emerging therapies; Immunosupression, Compatibilidad HLA; Terapias emergentes; Inmunosupresión, The ongoing shortage of cell, tissue, and organ donors has led to prioritizing clinical urgency over optimal immune matching in transplantation, often at the cost of increased reliance on immunosuppressive regimens and their associated adverse effects. Recent advances in the use of Substances of Human Origin (SoHOs), xenotransplantation and emerging cell-, gene-, and tissue-based therapies have enabled the development of tailored cellular therapeutics to enhance engraftment, long-term function, and immunological compatibility. Within this evolving context, artificial intelligence is also increasingly contributing to improve donor–recipient matching through predictive analytics and integrative data modeling, assisting on immune tolerance and the durable integration of transplanted cells into host tissues. In this review, we revisit foundational concepts of immunocompatibility, examine current clinical criteria in organ transplantation, and critically explore the shifting paradigms of donor–recipient matching in the era of personalized medicine. These advances have the potential to redefine clinical strategies in transplantation and regenerative care while ensuring patient access and sustainability., The author(s) declare financial support was received for the research and/or publication of this article. JV’s laboratory is a member of the Red Española de Terapias Avanzadas (RICORS-TERAV/TERAV+, file nos. RD21/0017/0022 and RD24/0014/0037, PI: JV), funded by the Instituto de Salud Carlos III (ISCiii) in the context of NextGenerationEU Recovery, Transformation and Resilience Plan. The joint BST-VHIR Musculoskeletal Tissue Engineering Group is a Consolidated Research Group accredited by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya (file no. 2021-SGR-00877). RG-A is recipient of a PhD fellowship from the VHIR PhD call funded by Vall Hebron Research Institute (VHIR) - Amics del VHIR.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial

  • Bayes-Genis, Antoni
  • Gastelurrutia, Paloma
  • Monguió-Tortajada, Marta
  • Camara, María-luisa
  • Prat-Vidal, Cristina
  • Cediel, Germán
  • Vives, Joaquim
Reparación cardíaca; Ingeniería de tejidos cardíacos; Infarto de miocardio, Reparació cardíaca; Enginyeria de teixits cardíacs; Infart de miocardi, Cardiac repair; Cardiac tissue engineering; Myocardial infarction, Background In preclinical studies, the use of double allogeneic grafts has shown promising results in promoting tissue revascularization, reducing infarct size, preventing adverse remodelling and fibrosis, and ultimately enhancing cardiac function. Building upon these findings, the safety of PeriCord, an engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells, was evaluated in the PERISCOPE Phase I clinical trial (NCT03798353), marking its first application in human subjects. Methods This was a double-blind, single-centre trial that enrolled patients with non-acute myocardial infarction eligible for surgical revascularization. Seven patients were implanted with PeriCord while five served as controls. Findings Patients who received PeriCord showed no adverse effects during post-operative phase and one-year follow-up. No significant changes in secondary outcomes, such as quality of life or cardiac function, were found in patients who received PeriCord. However, PeriCord did modulate the kinetics of circulating monocytes involved in post-infarction myocardial repair towards non-classical inflammation-resolving macrophages, as well as levels of monocyte chemoattractants and the prognostic marker Meteorin-like in plasma following treatment. Interpretation In summary, the PeriCord graft has exhibited a safe profile and notable immunomodulatory properties. Nevertheless, further research is required to fully unlock its potential as a platform for managing inflammatory-related pathologies., This work was supported in part by grants from MICINN (SAF2017-84324-C2-1-R); Instituto de Salud Carlos III (ICI19/00039 and Red RICORS-TERAV RD21/0017/0022, and CIBER Cardiovascular CB16/11/00403) as a part of the Plan Nacional de I + D + I, and co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER) and AGAUR (2021-SGR-01437).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells, Proof of Concept and Regulatory Compliance

  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Hernández Martín, Joaquim|||0000-0003-1409-5568
  • Mirabel, Clémentine
  • Puigdomenech-poch, Maria
  • Romeo-Guitart, David|||0000-0003-3368-9302
  • Marmolejo Martínez-Artesero, Sara|||0000-0001-5357-2123
  • Cabrera-Pérez, Raquel|||0000-0002-4858-0142
  • Jaramillo, Jessica
  • Kumru, Hatice|||0000-0002-0501-1660
  • García López, Joan
  • Vidal-Samsó, Joan
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
(1) Background: the use of Mesenchymal Stromal Cells (MSC) in emerging therapies for spinal cord injury (SCI) hold the potential to improve functional recovery. However, the development of cell-based medicines is challenging and preclinical studies addressing quality, safety and efficacy must be conducted prior to clinical testing; (2) Methods: herein we present (i) the characterization of the quality attributes of MSC from the Wharton's jelly (WJ) of the umbilical cord, (ii) safety of intrathecal infusion in a 3-month subchronic toxicity assessment study, and (iii) efficacy in a rat SCI model by controlled impaction (100 kdynes) after single (day 7 post-injury) and repeated dose of 1 × 10 MSC,WJ (days 7 and 14 post-injury) with 70-day monitoring by electrophysiological testing, motor function assessment and histology evaluation; (3) Results: no toxicity associated to MSC,WJ infusion was observed. Regarding efficacy, recovery of locomotion was promoted at early time points. Persistence of MSC,WJ was detected early after administration (day 2 post-injection) but not at days 14 and 63 post-injection. (4) Conclusions: the safety profile and signs of efficacy substantiate the suitability of the presented data for inclusion in the Investigational Medicinal Product Dossier for further consideration by the competent Regulatory Authority to proceed with clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

N-Glycans in Immortalized Mesenchymal Stromal Cell-Derived Extracellular Vesicles Are Critical for EV-Cell Interaction and Functional Activation of Endothelial Cells

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Williams, Charles
  • Reichardt, Niels-Christian
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Roura, Santiago|||0000-0003-4063-9661
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EV) are widely considered as a cell-free therapeutic alternative to MSC cell administration, due to their immunomodulatory and regenerative properties. However, the interaction mechanisms between EV and target cells are not fully understood. The surface glycans could be key players in EV-cell communication, being specific molecular recognition patterns that are still little explored. In this study, we focused on the role of N-glycosylation of MSC-EV as mediators of MSC-EV and endothelial cells' interaction for subsequent EV uptake and the induction of cell migration and angiogenesis. For that, EV from immortalized Wharton's Jelly MSC (iWJ-MSC-EV) were isolated by size exclusion chromatography (SEC) and treated with the glycosidase PNGase-F in order to remove wild-type N-glycans. Then, CFSE-labelled iWJ-MSC-EV were tested in the context of in vitro capture, agarose-spot migration and matrigel-based tube formation assays, using HUVEC. As a result, we found that the N-glycosylation in iWJ-MSC-EV is critical for interaction with HUVEC cells. iWJ-MSC-EV were captured by HUVEC, stimulating their tube-like formation ability and promoting their recruitment. Conversely, the removal of N-glycans through PNGase-F treatment reduced all of these functional activities induced by native iWJ-MSC-EV. Finally, comparative lectin arrays of iWJ-MSC-EV and PNGase-F-treated iWJ-MSC-EV found marked differences in the surface glycosylation pattern, particularly in N-acetylglucosamine, mannose, and fucose-binding lectins. Taken together, our results highlight the importance of N-glycans in MSC-EV to permit EV-cell interactions and associated functions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds

  • Martorell Cedres, Lluis|||0000-0001-9348-4531
  • López-Fernández, Alba|||0000-0001-6072-0294
  • García-Lizarribar, Andrea|||0000-0001-5072-2093
  • Sabata, Roger|||0000-0002-4769-4615
  • Galvez-Martin, Patricia|||0000-0001-9724-8560
  • Samitier, Josep|||0000-0002-1140-3679
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Three dimensional (3D) bioprinting is an emerging technology that enables complex spatial modeling of cell-based tissue engineering products, whose therapeutic potential in regenerative medicine is enormous. However, its success largely depends on the definition of a bioprintable zone, which is specific for each combination of cell-loaded hydrogels (or bioinks) and scaffolds, matching the mechanical and biological characteristics of the target tissue to be repaired. Therefore proper adjustment of the bioink formulation requires a compromise between: (i) the maintenance of cellular critical quality attributes (CQA) within a defined range of specifications to cell component, and (ii) the mechanical characteristics of the printed tissue to biofabricate. Herein, we investigated the advantages of using natural hydrogel-based bioinks to preserve the most relevant CQA in bone tissue regeneration applications, particularly focusing on cell viability and osteogenic potential of multipotent mesenchymal stromal cells (MSCs) displaying tripotency in vitro, and a phenotypic profile of 99.9% CD105/CD45, 10.3% HLA-DR, 100.0% CD90, and 99.2% CD73/CD31 expression. Remarkably, hyaluronic acid, fibrin, and gelatin allowed for optimal recovery of viable cells, while preserving MSC's proliferation capacity and osteogenic potency in vitro. This was achieved by providing a 3D structure with a compression module below 8.8 ± 0.5 kPa, given that higher values resulted in cell loss by mechanical stress. Beyond the biocompatibility of naturally occurring polymers, our results highlight the enhanced protection on CQA exerted by bioinks of natural origin (preferably HA, gelatin, and fibrin) on MSC, bone marrow during the 3D bioprinting process, reducing shear stress and offering structural support for proliferation and osteogenic differentiation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines, Good Practice for Better Therapies

  • Lopez-Navas, Luís
  • Torrents, Sílvia|||0000-0001-5563-8114
  • Sánchez-Pernaute, Rosario|||0000-0003-1144-9025
  • Vives, Joaquin
The development of cell-, gene-and tissue engineering (CGT)-based therapies must adhere to strict pharmaceutical quality management standards, as for any other biological or small-molecule drug. However, early developments often failed to fully comply with good laboratory practices (GLP) in non-clinical safety studies. Despite an upward trend of positive opinions in marketing authorization applications, evidence of adherence to the principles of GLP is not openly reported; therefore, their relative impact on the overall quality of the product development program is unknown. Herein we investigated the actual degree of GLP implementation and the underlying factors impeding full compliance in non-clinical developments of CGT-based marketed medicines in the EU and USA, including (i) the co-existence of diverse quality management systems of more strategic value for small organizations, particularly current Good Manufacturing Practices n(GMP); (ii) lack of regulatory pressure to pursue GLP certification; and (iii) the involvement of public institutions lacking a pharmaceutical mindset and resources. As a final reflection, we propose conformity to good research practice criteria not as a doctrinaire impediment to scientific work, but as a facilitator of efficient clinical translation of more effective and safer innovative therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells, Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft

  • Chaverri, Daniel
  • Gallardo-Villares, Santiago
  • Pinto, Javier A.
  • Rodríguez, Luciano
  • Codinach, Margarita|||0000-0003-0560-8798
  • García López, Joan
  • Querol, Sergi|||0000-0002-1105-8633
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Granell-Escobar, Fernando
Background: Atrophic pseudoarthrosis is a serious complication with an incidence of 5-10 % of bone fractures located in the diaphysis of long bones. Standard treatments involve aggressive surgical procedures and re-interventions requiring the use of autografts from the iliac crest as a source of bone-forming biological activity (Standard of Care, SoC). In this context, regenerative ex vivo expanded osteogenic cell-based medicines could be of interest. Particularly, Mesenchymal Stromal Cells (MSC) offer new prospects to promote bone tissue repair in pseudoarthrosis by providing biological activity in an osteoconductive and osteoinductive environment. Methods: We conducted a phase IIa, prospective, randomised, parallel, two-arms, open-label with blinded assessor pilot clinical trial to compare SoC vs. a tissue-engineered product (TEP), composed of autologous bone marrow (BM)-derived MSCs loaded onto allogeneic decellularised, lyophilised spongy bone cubes, in a cohort of 20 patients with non-hypertrophic pseudoarthrosis of long bones. Patients were followed up for 12 months. Radiological bone healing was evaluated by standard X-ray and computed tomography (CT) scanning. Quality of life was measured using the EUROQOL-5D questionnaire. Results: Ten patients were randomized to TEP and 10 to SoC with iliac crest autograft. Manufacturing of TEP was feasible and reproducibly achieved. TEP implantation in the bone defect was successful in all cases and none of the 36 adverse events (AE) reported were related to the treatment. Efficacy analyses were performed in the Full Analysis Set (FAS) population, which included 17 patients after 3 patients withdrew from the study. The degree of consolidation, estimated by measuring Hounsfield units (HU) on CT, showed no significant differences between the two treatment groups at 12 months post treatment (main efficacy variable) (p = 0.4835) or at 6 months. Conclusions: Although only a small number of patients were included in our study, it is notable that no significant differences were observed between the experimental treatment and SoC, thus suggesting TEP as an alternative where autograft is not available or contraindicated.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance

  • Vives Armengol, Joaquim
  • Hernandez, Joaquim
  • Clementine, Mirabel
  • Puigdomenech-Poch, Maria
  • Romeo-Guitart, David
  • Marmolejo Martínez-Artesero, Sara
  • Cabrera Perez, Raquel
Animal model; Cell therapy; Mesenchymal stromal cells, Modelo animal; Terapia celular; Células estromales mesenquimales, Model animal; Teràpia cel·lular; Cèl·lules estromals mesenquimàtiques, Background: the use of Mesenchymal Stromal Cells (MSC) in emerging therapies for spinal cord injury (SCI) hold the potential to improve functional recovery. However, the development of cell-based medicines is challenging and preclinical studies addressing quality, safety and efficacy must be conducted prior to clinical testing; (2) Methods: herein we present (i) the characterization of the quality attributes of MSC from the Wharton’s jelly (WJ) of the umbilical cord, (ii) safety of intrathecal infusion in a 3-month subchronic toxicity assessment study, and (iii) efficacy in a rat SCI model by controlled impaction (100 kdynes) after single (day 7 post-injury) and repeated dose of 1 × 106 MSC,WJ (days 7 and 14 post-injury) with 70-day monitoring by electrophysiological testing, motor function assessment and histology evaluation; (3) Results: no toxicity associated to MSC,WJ infusion was observed. Regarding efficacy, recovery of locomotion was promoted at early time points. Persistence of MSC,WJ was detected early after administration (day 2 post-injection) but not at days 14 and 63 post-injection. (4) Conclusions: the safety profile and signs of efficacy substantiate the suitability of the presented data for inclusion in the Investigational Medicinal Product Dossier for further consideration by the competent Regulatory Authority to proceed with clinical trials., This work has been developed in the context of the Spanish Cell Therapy Network (TerCel, expedient No.’s RD16/0011/0014, RD16/0011/0028 and RD16/00111/0036) and supported by Fundació La Marató de TV3 (grant No. 616/2012) and BST internal funding. Work in J.G.-L.’s laboratory is supported by the Spanish Advanced Therapy Network funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III (TERAV, expedient No.’s RD21/0017/0008 and RD21/0017/0022), CIBERNED (CB06/05/1105), and J.V.’s laboratory is a Consolidated Research Group (ref. 2017SGR719) by the Generalitat de Catalunya.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial

  • Bayes-Genis, Antoni
  • Gastelurrutia, Paloma
  • Monguió-Tortajada, Marta
  • Camara, María-luisa
  • Prat-Vidal, Cristina
  • Cediel, Germán
  • Vives, Joaquim
Reparación cardíaca; Ingeniería de tejidos cardíacos; Infarto de miocardio, Reparació cardíaca; Enginyeria de teixits cardíacs; Infart de miocardi, Cardiac repair; Cardiac tissue engineering; Myocardial infarction, Background In preclinical studies, the use of double allogeneic grafts has shown promising results in promoting tissue revascularization, reducing infarct size, preventing adverse remodelling and fibrosis, and ultimately enhancing cardiac function. Building upon these findings, the safety of PeriCord, an engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells, was evaluated in the PERISCOPE Phase I clinical trial (NCT03798353), marking its first application in human subjects. Methods This was a double-blind, single-centre trial that enrolled patients with non-acute myocardial infarction eligible for surgical revascularization. Seven patients were implanted with PeriCord while five served as controls. Findings Patients who received PeriCord showed no adverse effects during post-operative phase and one-year follow-up. No significant changes in secondary outcomes, such as quality of life or cardiac function, were found in patients who received PeriCord. However, PeriCord did modulate the kinetics of circulating monocytes involved in post-infarction myocardial repair towards non-classical inflammation-resolving macrophages, as well as levels of monocyte chemoattractants and the prognostic marker Meteorin-like in plasma following treatment. Interpretation In summary, the PeriCord graft has exhibited a safe profile and notable immunomodulatory properties. Nevertheless, further research is required to fully unlock its potential as a platform for managing inflammatory-related pathologies., This work was supported in part by grants from MICINN (SAF2017-84324-C2-1-R); Instituto de Salud Carlos III (ICI19/00039 and Red RICORS-TERAV RD21/0017/0022, and CIBER Cardiovascular CB16/11/00403) as a part of the Plan Nacional de I + D + I, and co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER) and AGAUR (2021-SGR-01437).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Immunocompatibility in transplantation: adapting to a changing therapeutic landscape

  • Güell-Alonso, Raquel
  • Cabrera Pérez, Raquel
  • Vives, Joaquim
Compatibilitat HLA; Teràpies emergents; Immunosupressió, HLA match; Emerging therapies; Immunosupression, Compatibilidad HLA; Terapias emergentes; Inmunosupresión, The ongoing shortage of cell, tissue, and organ donors has led to prioritizing clinical urgency over optimal immune matching in transplantation, often at the cost of increased reliance on immunosuppressive regimens and their associated adverse effects. Recent advances in the use of Substances of Human Origin (SoHOs), xenotransplantation and emerging cell-, gene-, and tissue-based therapies have enabled the development of tailored cellular therapeutics to enhance engraftment, long-term function, and immunological compatibility. Within this evolving context, artificial intelligence is also increasingly contributing to improve donor–recipient matching through predictive analytics and integrative data modeling, assisting on immune tolerance and the durable integration of transplanted cells into host tissues. In this review, we revisit foundational concepts of immunocompatibility, examine current clinical criteria in organ transplantation, and critically explore the shifting paradigms of donor–recipient matching in the era of personalized medicine. These advances have the potential to redefine clinical strategies in transplantation and regenerative care while ensuring patient access and sustainability., The author(s) declare financial support was received for the research and/or publication of this article. JV’s laboratory is a member of the Red Española de Terapias Avanzadas (RICORS-TERAV/TERAV+, file nos. RD21/0017/0022 and RD24/0014/0037, PI: JV), funded by the Instituto de Salud Carlos III (ISCiii) in the context of NextGenerationEU Recovery, Transformation and Resilience Plan. The joint BST-VHIR Musculoskeletal Tissue Engineering Group is a Consolidated Research Group accredited by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya (file no. 2021-SGR-00877). RG-A is recipient of a PhD fellowship from the VHIR PhD call funded by Vall Hebron Research Institute (VHIR) - Amics del VHIR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance

  • Vives Armengol, Joaquim
  • Sòria, Maria Glòria
  • McGrath, Eoin
  • Magri, Mara
Integrated management system; Quality compliance; Quality standards, Sistema de gestión integrado; Cumplimiento de la calidad; Estándares de calidad, Sistema de gestió integrat; Compliment de la qualitat; Estàndards de qualitat, Cell therapies are required to meet with compulsory regulations that co-exist with other optional standards and guidelines that together compose a complex quality management system. Indeed, reliable insights on the mechanisms of action and safety of novel cell-based therapies require adherence to solid quality management structures in all steps of the value chain, from early research and tissue procurement to clinical trials and biovigilance, thus guaranteeing reproducibility and solid foundations for better science and improved clinical practice. Herein we present the concept of the quality ecosystem as a tool to understand and assist all stakeholders involved in developing and structuring the integration of standards as novel developments are taking place. We conclude that the various quality management initiatives can all be thought about under the umbrella of an ecosystem., Work in JV’s laboratory is supported by the Spanish Advanced Therapy Network (TERAV, expedient No. RD21/0017/0022), awarded by the Generalitat de Catalunya as Consolidated Research Group (ref. 2017SGR719) and funded by Ministerio de Ciencia Innovación y Universidades de España (Instituto de Salud Carlos III, expedient No. PI19/01788).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use

  • Torrents, Sílvia
  • Escudero del Moral, Andrés
  • Codinach, Margarita
  • Rodríguez Gómez, Luciano
  • Querol, Sergio
  • Vives, Joaquim
Immunomodulation; Mesenchymal stromal cells; Quality & regulatory compliance, Immunomodulació; Cèl·lules estromals mesenquimàtiques; Qualitat i compliment normatiu, Inmunomodulación; Células estromales mesenquimales; Calidad y cumplimiento normativo, Multipotent mesenchymal stromal cells (MSC) offer new therapeutic opportunities based on their ability to modulate an imbalanced immune system. Immunomodulatory potency is typically demonstrated in vitro by measuring the presence of surrogate markers (i.e., indoleamine-2,3-dioxygenase, IDO; tumor necrosis factor receptor type 1, TNFR1) and/or functional assays in co-cultures (i.e., inhibition of lymphoproliferation, polarization of macrophages). However, the biological variability of reagents used in the latter type of assays leads to unreliable and difficult to reproduce data therefore making cross-comparison between batches difficult, both at the intra- and inter-laboratory levels. Herein, we describe a set of experiments aiming at the definition and validation of reliable biological reagents as a first step towards standardization of a potency assay. This approach is based on the co-culture of Wharton’s jelly (WJ)-derived MSC and cryopreserved pooled peripheral blood mononuclear cells. Altogether, we successfully defined a robust and reproducible immunopotency assay based on previously described methods incorporating substantial improvements such as cryopreservation of multiple vials of pooled peripheral blood mononuclear cells (PBMC) from 5 individual donors that enable a number of tests with same reagents, also reducing waste of PBMC from individual donors and therefore contributing to a more efficient and ethical method to use substances of human origin (SoHO). The new methodology was successfully validated using 11 batches of clinical grade MSC,WJ. Methods described here contribute to minimize PBMC donor variability while reducing costs, streamlining assay setup and convenience and laying the foundations for harmonization of biological reagents usage in standardized immunopotency assays for MSC., Open Access Funding provided by Universitat Autonoma de Barcelona. This work has been developed in the context of Red Española de Terapias Avanzadas (TERAV, expedient no. RD21/0017/0022) funded by Instituto de Salud Carlos III (ISCIII) in the context of NextGenerationEU’s Recovery, Transformation and Resilience Plan and by the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (2017 SGR 719).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies

  • López Navas, Luis
  • Sílvia Torrents
  • Sanchez-Pernaute, Rosario
  • Vives Armengol, Joaquim
Non-clinical safety; Product development; Quality compliance, Seguridad no clínica; Desarrollo de productos; Cumplimiento de calidad, Seguretat no clínica; Desenvolupament de productes; Compliment de la qualitat, The development of cell-, gene- and tissue engineering (CGT)-based therapies must adhere to strict pharmaceutical quality management standards, as for any other biological or small-molecule drug. However, early developments often failed to fully comply with good laboratory practices (GLP) in non-clinical safety studies. Despite an upward trend of positive opinions in marketing authorization applications, evidence of adherence to the principles of GLP is not openly reported; therefore, their relative impact on the overall quality of the product development program is unknown. Herein we investigated the actual degree of GLP implementation and the underlying factors impeding full compliance in non-clinical developments of CGT-based marketed medicines in the EU and USA, including (i) the co-existence of diverse quality management systems of more strategic value for small organizations, particularly current Good Manufacturing Practices n(GMP); (ii) lack of regulatory pressure to pursue GLP certification; and (iii) the involvement of public institutions lacking a pharmaceutical mindset and resources. As a final reflection, we propose conformity to good research practice criteria not as a doctrinaire impediment to scientific work, but as a facilitator of efficient clinical translation of more effective and safer innovative therapies., The authors received no specific funding for this work, which has been developed in the context of Red Española de Terapias Avanzadas (TERAV, expedient no.’s RD21/0017/0015 and RD21/0017/0022) funded by Instituto de Salud Carlos III (ISCIII) in the context of NextGenerationEU’s Recovery, Transformation and Resilience Plan.